EW Form 4: Executive receives RSUs and reports small share sale at $77.57

Rhea-AI Filing Summary

Edwards Lifesciences director and officer Wayne Markowitz reported two transactions in September 2025 affecting his holdings in Edwards Lifesciences (EW). On 09/11/2025 he was granted 6,410 restricted stock units (RSUs) under the companys Long-Term Stock Incentive Compensation Program; those RSUs vest in four equal annual installments beginning one year after the grant date. On 09/14/2025 he sold 650 shares of common stock at a price of $77.57 per share. After these transactions he beneficially owns 18,145.8708 shares directly. The Form 4 notes the RSU grant and also references quarterly ESPP share acquisitions; no derivative transactions were reported.

Positive

• Grant of 6,410 RSUs aligns executive compensation with long-term shareholder value through multi-year vesting
• Vesting schedule disclosed: four equal annual installments beginning one year after grant, improving transparency
• Form 4 includes ESPP acquisitions, indicating participation in company employee stock purchase programs

Negative

• Open-market sale of 650 shares at $77.57 reduced reported direct holdings, though amount appears modest
• Filing does not specify total share count beyond reported beneficial ownership of 18,145.8708 shares, limiting full ownership context

Insights

Financial Analyst

TL;DR: Routine executive equity grant and a small open-market sale; not a material change to ownership.

The 6,410 RSU grant is a compensation event reflecting long-term incentives rather than immediate cash flow, with vesting over four years which ties the reporting person to multi-year performance or retention. The 650-share sale at $77.57 is modest relative to the total reported holding of 18,795.8708 before the sale and 18,145.8708 after, suggesting routine liquidity rather than a significant change in exposure. No options or other derivatives were reported, and the filing flags regular ESPP acquisitions. From a financial perspective this filing contains typical insider compensation and minor disposition activity.

Corporate Governance Expert

TL;DR: Governance-wise this is a standard Form 4 disclosure of compensation and a small disposition, consistent with expected insider reporting.

The RSU award under the Long-Term Stock Incentive Compensation Program and the detailed vesting schedule meet disclosure norms by specifying grant date and vesting cadence. The filing includes an attorney-in-fact signature and identifies the reporting persons role as CVP, JAPAC and director/officer, which clarifies reporting obligations. The sale price and number of shares sold are disclosed, and the filing notes ESPP purchases, providing transparency on common employee equity activity. No governance red flags or unusual transactions are evident in the document itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Markowitz Wayne

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, JAPAC

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		A		6,410(1)	A	$0.0000	18,795.8708	D
Common Stock	09/14/2025		F		650	D	$77.57	18,145.8708	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units were granted on September 11, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

	Linda J. Park, Attorney-in-Fact	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Wayne Markowitz report for Edwards Lifesciences (EW)?

The Form 4 reports a 6,410 RSU grant on 09/11/2025 and a sale of 650 shares on 09/14/2025 at $77.57 per share.

When do the restricted stock units (RSUs) granted to Markowitz vest?

The RSUs are scheduled to vest in four equal annual installments commencing one year after the grant date (09/11/2025).

How many shares does Markowitz beneficially own after these transactions?

Following the reported transactions, the Form 4 shows Markowitz beneficially owns 18,145.8708 shares directly.

Was any derivative or option activity reported in this Form 4?

No derivative securities, options, puts, calls, or convertible security transactions are reported in Table II of the filing.

Did the filing indicate participation in an Employee Stock Purchase Plan (ESPP)?

Yes, the remarks state the Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.